Wealth Enhancement Trust Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealth Enhancement Trust Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.21K	Buy	+126	New	+$6.9K	﹤0.01%	781

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Trust Services's BMRN Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 126 shares worth $7.21K. The stake represents ﹤0.01% of the portfolio and ranks #781 among its holdings.

413 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Wealth Enhancement Trust Services held 126 shares of BioMarin Pharmaceuticals worth $7.21K as of Q2 2026.
BioMarin Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #781 holding.
413 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.